Insider · CIK 0001621788
Ali J. Satvat
director
Files at CHRS (Coherus Oncology, Inc.), BBIO (BridgeBio Pharma, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | AGrant or award Common Stock | +6,589 | $0.00 | $0 | 165,993 | Jun 24, 2025 |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,425 | $0.00 | $0 | 8,425 | Jun 24, 2025 |
| Jun 12, 2025 | CHRS Coherus Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | MOption exercise Common Stock | +79,702 | $10.99 | $876k | 79,702 | Dec 31, 2024 |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | MOption exercise Common Stock | +39,851 | $16.68 | $665k | 119,553 | Dec 31, 2024 |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | MOption exercise Common Stock | +39,851 | $26.21 | $1.0M | 159,404 | Dec 31, 2024 |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -79,702 | $0.00 | $0 | 0 | Dec 31, 2024 |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -39,851 | $0.00 | $0 | 0 | Dec 31, 2024 |
| Dec 30, 2024 | BBIO BridgeBio Pharma, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -39,851 | $0.00 | $0 | 0 | Dec 31, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.